GT Biopharma GTBP
NASDAQ GTBP
$6.98 +0.18 (+2.65%)
As of: Sep 30, 2026 · 10:18 AM EDT

GT Biopharma (GTBP) EBITDA Margin (2015)

Updated

GT Biopharma (GTBP) posted EBITDA Margin of -33055.56% for FY2015, down 29163.75 percentage points from -3891.80% in FY2014.

Analysis

GT Biopharma (GTBP) EBITDA Margin (2015) Analysis & Trends

  • Business Quant data shows GTBP's EBITDA Margin at -3891.80% in FY2014.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 35.95%
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 49.01%
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 6.02%
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn 33.11%
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 46.01%
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn -124.26%
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 39.16%
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 39.10%
10 GT Biopharma 9.57 Mn 9.57 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2015 -7,155.00%
Mar 31, 2015 -25,857.14%
API Access

GT Biopharma EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=GTBP&period=max&api_key=YOUR_API_KEY